Scarica l'app Stockscreener
13.07
1.55%
0.20
Dopo l'orario di chiusura:
13.09
0.02
+0.15%
Precedente Chiudi:
$12.87
Aprire:
$13.02
Volume 24 ore:
2.14M
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.23B
Reddito:
-
Utile/perdita netta:
$-313.94M
Rapporto P/E:
-3.7279
EPS:
-3.506
Flusso di cassa netto:
$-284.57M
1 W Prestazione:
+1.16%
1M Prestazione:
-16.11%
6M Prestazione:
+93.34%
1 anno Prestazione:
+277.75%
Intervallo 1D:
$12.68
$13.20
Intervallo di 1 settimana:
$12.46
$13.64
Portata 52W:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
13.07 | 1.22B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Downgrade | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Downgrade | Jefferies | Buy → Hold |
| 2026-04-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-04-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Stock DropRobbins LLP Reminds Investors They May Be - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class ActionContact Levi & Korsinsky - Business Wire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead - TradingView
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of - GlobeNewswire
Replimune faces class action over alleged nondi... - Pluang
Replimune at cantor healthcare conference: careful launch, broad pipeline By Investing.com - Investing.com Canada
REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact SueWallSt - PR Newswire
Class action lawsuit filed against Replimune fo... - Pluang
Replimune faces securities lawsuit over alleged misleading FDA trial data claims, stock plunged 84%. - Pluang
REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Replimune Group Stock Short Interest Falls to 43.08% - moomoo.com
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Price to earnings forward of Replimune Group, Inc. – NASDAQ:REPL - TradingView
2026-09-06 | REPL SHAREHOLDER ALERT - Stockhouse
Avoiding Lag: Real-Time Signals in (REPL) Movement - Stock Traders Daily
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - Eastern Progress
Replimune shares plunge 84% after FDA rejects R... - Pluang
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune investors urged to seek lead plaintiff role by Oct 5 deadline - scanx.trade
Class action lawsuit filed against Replimune af... - pluang.com
REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune to Present at the Cantor Global Healthcare Conference 2026 - The Manila Times
Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc. - Business Wire
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Morningstar
Replimune Group stock hits 52-week high at 16.2 USD By Investing.com - Investing.com Canada
Replimune Group stock hits 52-week high at 16.2 USD - Investing.com
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of - GlobeNewswire
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact SueWallSt - PR Newswire
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Replimune Group stock hits 52-week high at 15.72 USD By Investing.com - Investing.com Nigeria
REPL Deadline Alert: Levi & Korsinsky Reminds Replimune - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - Eastern Progress
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop - TipRanks
Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action - PR Newswire
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Stocktwits
Replimune (REPL) Results at a Glance: Profit Per Share Falls Below Its Benchmark; Market Response: Shares Move Lower 3.31% in the Available RecordFinancial Summary - vinanet.vn
REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Chief Executive Officer |
Aug 10 '26 |
Sale |
12.97 |
39,341 |
510,253 |
708,151 |
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):